Previous 10 | Next 10 |
2023-05-23 07:16:13 ET German biotech Affimed N.V. ( NASDAQ: AFMD ) announced Tuesday that the FDA cleared an Investigational New Drug Application (IND) permitting a Phase 2 trial to study its innate cell engager AFM13 as a combination therapy for certain patients with Hodgkin Lymph...
2023-05-23 06:33:15 ET Affimed press release ( NASDAQ: AFMD ): Q1 GAAP EPS of -€0.21. Revenue of €4.51M (-43.7% Y/Y). As of March 31, 2023 cash and cash equivalents totaled €155.8 million compared to €190.3 million on December 31, 2022....
AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL) and peripheral T Cell Lymphoma (PTCL). Affimed expects to initiate clinical trial in Q3 2023...
Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phase Primary endpoints of the study are to assess the ant...
2023-05-22 12:53:45 ET Affimed ( NASDAQ: AFMD ) is scheduled to announce Q1 earnings results on Tuesday, May 23rd, before market open. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $6.18M. Over the last 3 months, EPS estimates have seen 0 ...
2023-05-22 11:07:30 ET Major earnings expected before the bell on Tuesday include: DICK'S Sporting Goods ( DKS ) Eagle Point Credit ( ECC ) Jumia Technologies ( JMIA ) Lowe's Companies ( LOW ) Navios Maritime Partners ( NMM ) For further detai...
HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May ...
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentation A trial in progress abstract of the phase 1 dose escalation study to assess safety and tolerability of AFM28 monotherapy...
AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentation AFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online publication HEIDELBERG, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Affimed N.V....
The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cells It demonstrates the potential of AFM13 to induce serial killing, even in tumor cells with low target expression HEIDELBERG, Germany, April 17, 2023 (GLOBE NEW...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...